Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: metronidazole gel applied topically after periodontal debridement in smokers volunteers could improve clinical parameters when compared to metronidazole tablets + periodontal debridement. Method: 30 smokers with chronic periodontitis were randomly assigned into 3 groups: periodontal debridement combined with 3 g placebo gel; periodontal debridement combined with daily topical application of 3 g metronidazole benzoate gel (15%); and periodontal debridement combined with a daily single dose of 750 mg metronidazole. Clinical parameters evaluated were visible plaque, gingival bleeding, probing pocket depth and relative attachment level.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Campinas, Brazil
• Collaborator: Faculty Sao Leopoldo Mandic Campinas
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• diagnosis of chronic periodontitis

• presence of at least 6 periodontal pockets with a clinical attachment loss of ≥5 mm

• bleeding on probing (BOP)

• radiographic bone loss

• probing pocket depth higher or equal to 5 mm in at least six teeth

• at least 20 teeth in mouth (third molars excluded)

• an established smoking habit (at least 10 cigarettes per day for the past 4 years)

Exclusion Criteria:

• periapical alterations in qualifying teeth

• medical disorders requiring prophylactic antibiotic therapy or interfering with the treatment

• periodontal treatment in the past 6 months

• use of drugs known to affect periodontal status (antibiotic, anti-inflammatory, anticonvulsant, immunosuppressant and calcium channel blocker) within the past 6 months

• orthodontic therapy

• pregnancy and lactation

• allergy to metronidazole

• any systemic diseases (e.g.: diabetes and immunological disorders)